BLCO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.38B

+8.12%

0.355

+42.06%

1.21B

+6.59%

0.074

-206.36%

1.36B

+6.07%

0.168

+140.01%

Estimates Revision

The market is revising Downward the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by 11.49%.

Revenue Estimates for FY2025

Revise Downward

-0.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+8.3%

In Past 3 Month

Stock Price

Go Up

+11.49%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast BLCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 16.10 USD with a low forecast of 13.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

8 Hold

1 Sell

Hold

Current: 16.980

Low

13.00

Averages

16.10

High

19.00

Current: 16.980

Low

13.00

Averages

16.10

High

19.00

Morgan Stanley

Overweight

maintain

$21

2025-12-03

Reason

Morgan Stanley

Price Target

$21

2025-12-03

maintain

Overweight

Reason

Morgan Stanley reiterated an Overweight rating and $21 price target on Bausch + Lomb (BLCO), saying its CVS (CVS) commercial agreement over Xiidra ending is probably a good thing. Given that such a move was well anticipated, the firm understands that management still expects Xiidra to grow revenues in 2026, and while total prescriptions will be lower, the revenue impact is very modest given the big gross tot net dynamics here on low actual pricing, the analyst tells investors in a research note. The firm added that Xiidra margins overall should move up, marking a solid signal around pricing discipline within the industry overall.

Morgan Stanley

Equal Weight -> Overweight

upgrade

$14 -> $21

2025-12-02

Reason

Morgan Stanley

Price Target

$14 -> $21

2025-12-02

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Bausch + Lomb to Overweight from Equal Weight with a price target of $21, up from $14.

Morgan Stanley

Equal Weight -> Overweight

upgrade

$14 -> $21

2025-12-02

Reason

Morgan Stanley

Price Target

$14 -> $21

2025-12-02

upgrade

Equal Weight -> Overweight

Reason

As previously reported, Morgan Stanley upgraded Bausch + Lomb to Overweight from Equal Weight with a price target of $21, up from $14. The firm believes that the company has the strongest pipeline within ophthalmology and represents up to a $7B per year opportunity with many of the products coming down the pipe "amongst the most interesting and disruptive within both ophthalmology and healthcare overall," the analyst tells investors. While noting that most of the pipeline is coming in 2028 and beyond, there are "several key assets that are noteworthy" with efficiency measures driving margins up shorter-term, creating "a compelling financial profile over the next 2-3 years," the analyst added.

RBC Capital

Outperform

maintain

$17 -> $19

2025-11-14

Reason

RBC Capital

Price Target

$17 -> $19

2025-11-14

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Bausch + Lomb to $19 from $17 and keeps an Outperform rating on the shares. The company's Investor Day highlighted the significant operating leverage within the business, while the management also emphasized its robust pipeline, pointing to a steady stream of product launches over the next decade and an estimated peak sales potential of $7B, the analyst tells investors in a research note.

Barclays

Equal Weight

maintain

$16 -> $17

2025-10-31

Reason

Barclays

Price Target

$16 -> $17

2025-10-31

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Bausch + Lomb to $17 from $16 and keeps an Equal Weight rating on the shares. The firm updated the company's estimates to reflect the Q3 earnings beat.

H.C. Wainwright

Buy

maintain

$16 -> $17

2025-10-31

Reason

H.C. Wainwright

Price Target

$16 -> $17

2025-10-31

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Bausch + Lomb to $17 from $16 and keeps a Buy rating on the shares. The company reported a Q3 beat and reiterates its 2025 outlook, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Bausch + Lomb Corp (BLCO.N) is 20.43, compared to its 5-year average forward P/E of 21.17. For a more detailed relative valuation and DCF analysis to assess Bausch + Lomb Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

21.17

Current PE

20.43

Overvalued PE

25.26

Undervalued PE

17.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.58

Current EV/EBITDA

10.67

Overvalued EV/EBITDA

11.35

Undervalued EV/EBITDA

9.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.27

Current PS

1.14

Overvalued PS

1.49

Undervalued PS

1.04

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BLCO News & Events

Events Timeline

No data

News

8.5

12-12Yahoo Finance

PinnedBausch + Lomb Restructures Existing Term B Loans

7.5

12-12Newsfilter

Bausch + Lomb Allocates $2.8B for Loan Refinancing

8.5

12-12SeekingAlpha

Bausch + Lomb secures $2.8 billion in new term loans to refinance current debt.

People Also Watch

Frequently Asked Questions

What is Bausch + Lomb Corp (BLCO) stock price today?

The current price of BLCO is 16.98 USD — it has decreased -0.06 % in the last trading day.

What is Bausch + Lomb Corp (BLCO)'s business?

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

What is the price predicton of BLCO Stock?

What is Bausch + Lomb Corp (BLCO)'s revenue for the last quarter?

Bausch + Lomb Corp revenue for the last quarter amounts to 1.28B USD, increased 7.11 % YoY.

What is Bausch + Lomb Corp (BLCO)'s earnings per share (EPS) for the last quarter?

Bausch + Lomb Corp. EPS for the last quarter amounts to -0.08 USD, decreased -900.00 % YoY.

What changes have occurred in the market's expectations for Bausch + Lomb Corp (BLCO)'s fundamentals?

How many employees does Bausch + Lomb Corp (BLCO). have?

Bausch + Lomb Corp (BLCO) has 13500 emplpoyees as of December 15 2025.

What is Bausch + Lomb Corp (BLCO) market cap?

Today BLCO has the market capitalization of 6.02B USD.